Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.

被引：0
|
作者：
Konecny, Gottfried E.
Hendrickson, Andrea Elisabeth Wahner
Winterhoff, Boris
Chander, Cinthiya
Bilic, Sanela
Davenport, Simon
Chung, Adrine
Miller, Lei-Lani
Press, Michael F.
Letrent, Stephen P.
Slamon, Dennis J.
机构：
[1] Univ Calif Los Angeles Med Ctr, Santa Monica, CA USA
[2] Mayo Clin, Rochester, MN USA
[3] Univ Minnesota, Div Gynecol Oncol, Minneapolis, MN USA
[4] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA
[5] Vanadro LLC, Urbandale, IA USA
[6] Univ Southern Calif, Los Angeles, CA USA
[7] Translat Res Oncol US, Los Angeles, CA USA
[8] TORL Biotherapeut, Culver City, CA USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3082
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Machado, A.
    Chander, C.
    Davenport, S.
    Bilic, S.
    Miller, L. L.
    Chung, A.
    Press, M. F.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [2] FIRST-IN-HUMAN PHASE 1 STUDY OF TORL-1-23, A NOVEL CLAUDIN 6 (CLDN6) TARGETED ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH OVARIAN CANCER
    Konecny, Gottfried
    Hendrickson, Andrea Wahner
    Winterhoff, Boris
    Chander, Cinthiya
    Bilic, Sanela
    Davenport, Simon
    Chung, Adrine
    Miller, Lei-Lani
    Press, Michael
    Letrent, Stephen
    Slamon, Dennis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A67 - A67
  • [3] Phase I, two-part, mutlicenter, first-in-human (FIH) study of TORL-1-23, a novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patients with advanced solid tumors
    Konecny, Gottfried
    Hendrickson, Andrea Wahner
    Winterhoff, Boris
    Kung, Adrine
    Miller, Lei-Lani
    Press, Michael
    Qazi, Ibrahim
    Scholler, Nathalie
    Dokainish, Hatem
    Letrent, Stephen
    Slamon, Dennis
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_3) : A56 - A56
  • [4] Phase I, two-part, multicenter first-in-human (FIH) study of TORL-1-23: A novel claudin 6 (CLDN6) targeting antibody drug conjugate (ADC) in patient with advanced solid tumors
    Konecny, G. E.
    Hendrickson, A. E. Wahner
    Winterhoff, B.
    Adjei, A. A.
    Kung, A.
    Miller, L-L.
    Press, M. F.
    Qazi, I.
    Scholler, N.
    Dokainish, H.
    Letrent, S.
    Slamon, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S551 - S551
  • [5] Preliminary results from a phase I, first-in-human study of DS-9606a, a claudin 6 (CLDN6)-directed antibody-drug conjugate (ADC), in patients (pts) with tumor types known to express CLDN6
    Patel, M. R.
    Hamilton, E. P.
    Piha-Paul, S. A.
    Henry, J.
    Banerji, U.
    Al Hallak, M. N.
    Okada, H.
    Qian, M.
    Zhang, X.
    Said, N.
    Chatikhine, V.
    Fontana, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S488 - S489
  • [6] A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)
    Hollebecque, Antoine
    Lopez, Juanita
    Piha-Paul, Sarina
    Dowlati, Afshin
    Patnaik, Amita
    Galvao, Vladimir
    Buckorny, Bruno
    Sehgal, Kartik
    Kingsley, Edwin
    Sanborn, Rachel
    Peters, Solange
    Sun, Yan
    Patilea-Vrana, Gabriela
    Nazarenko, Natalya
    Calvo, Emiliano
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A763 - A763
  • [7] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors.
    Bendell, Johanna
    Blumenschein, George
    Zinner, Ralph
    Hong, David
    Jones, Suzanne
    Infante, Jeffrey
    Burris, Howard
    Rajagopalan, Prabhu
    Kornacker, Martin
    Henderson, David
    Kelly, Andrea
    Hassan, Raffit
    CANCER RESEARCH, 2013, 73 (08)
  • [8] A first-in-human (FIH) phase 1 study of SHR-A1921, a TROP-2 targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors
    Wang, Jie
    Wu, Lin
    Song, Zhengbo
    Li, Xingya
    Liu, Caigang
    Liu, Tianshu
    Wu, Yiwen
    Zhang, Ze
    Wang, Shuni
    CANCER RESEARCH, 2023, 83 (08)
  • [9] First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.
    Demetri, George D.
    Luke, Jason J.
    Hollebecque, Antoine
    Powderly, John D.
    Spira, Alexander I.
    Subbiah, Vivek
    Lai, Dominic W.
    Yue, Huibin
    Kasichayanula, Sreeneeranj
    Gulbranson, Scott
    Purcell, James
    Myzak, Melinda
    Robinson, Randy
    Villalobos, Victor Manuel
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors.
    Chandana, Sreenivasa R.
    Choudhury, Noura J.
    Dowlati, Afshin
    Chiang, Anne C.
    Garmezy, Benjamin
    Kim, Joo-Hang
    Byers, Lauren Averett
    Ahn, Myung-Ju
    Kim, Tae Min
    Kim, Young-Chul
    Han, Ji-Youn
    Bar, Jair
    Zha, Jiuhong
    Henner, William
    Robinson, Randy
    Kohlhapp, Fred
    Hingorani, Pooja
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345